PhaseBio Pharmaceuticals Property, Plant, Equpment (Net)

Property, Plant, Equpment (Net) of PHAS for past 10 years: annual, quarterly and twelve month trailing (TTM) including Property, Plant, Equpment (Net) growth rates and interactive chart. Property, plant, and equipment (aslo called PP&E) are a company's physical or tangible long-term assets that typically have a life of more than one year. Examples of PP&E include buildings, machinery, land, office equipment, furniture, and vehicles.


Highlights and Quick Summary

  • Property, Plant, Equpment (Net) for the quarter ending September 29, 2021 was $12.4 Million (a 2.87% increase compared to previous quarter)
  • Year-over-year quarterly Property, Plant, Equpment (Net) increased by 22.42%
  • Annual Property, Plant, Equpment (Net) for 2020 was $10.2 Million (a 178.95% increase from previous year)
  • Annual Property, Plant, Equpment (Net) for 2019 was $3.64 Million (a 925.07% increase from previous year)
  • Annual Property, Plant, Equpment (Net) for 2018 was $355 Thousand (a 17.55% increase from previous year)
Visit stockrow.com/PHAS for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Property, Plant, Equpment (Net) of PhaseBio Pharmaceuticals

Most recent Property, Plant, Equpment (Net)of PHAS including historical data for past 10 years.

Interactive Chart of Property, Plant, Equpment (Net) of PhaseBio Pharmaceuticals

PhaseBio Pharmaceuticals Property, Plant, Equpment (Net) for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 $12.43 $12.08 $12.61
2020 $10.15 $8.2 $4.88 $2.64 $10.15
2019 $1.92 $1.02 $0.68 $0.38 $3.64
2018 $0.36 $0.25 $0.36
2017 $0.3
2016 $0.18

Business Profile of PhaseBio Pharmaceuticals

Sector: Healthcare
Industry: Biotechnology
PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiopulmonary diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or emergency surgery. The company is also developing PB1046, a vasoactive intestinal peptide analogue that is in Phase IIb clinical trial for the treatment of pulmonary arterial hypertension; and PB6440 for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was incorporated in 2002 and is based in Malvern, Pennsylvania.